Your prediction
Alterity Therapeutics Ltd. ADR Stock
Pros and Cons of Alterity Therapeutics Ltd. ADR in the next few years
Pros
Cons
Performance of Alterity Therapeutics Ltd. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alterity Therapeutics Ltd. ADR | -7.090% | -0.781% | -16.447% | -32.357% | -32.357% | -5.926% | -77.138% |
| TALI Digital Ltd. | -11.490% | -5.435% | 8600.000% | 8600.000% | 8600.000% | 8600.000% | 117.500% |
| Immutep Ltd. | 4.950% | 6.316% | 38.356% | 1.000% | -0.980% | 7.447% | -21.094% |
| Invion Ltd | 2.780% | -6.494% | 18.033% | -78.049% | -80.000% | 2300.000% | 1340.000% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Diving into the financials of Alterity Therapeutics, a player in the dynamic Biotechnology & Medical Research industry, presents an intriguing puzzle. A cursory glance at the numbers indicates a company that is navigating the challenging waters of a sector known for its hefty R&D expenses and long gestation periods before achieving profitability.
Examining the company's financial ratios, we notice that the Market Capitalization stands at $15.27 million, suggesting a small-cap entity which is common in this high-risk, high-reward sector. The absence of ratios like P/E (Price to Earnings), PEG (Price/Earnings to Growth), and Wall Street Target Price propels one towards a more cautious stance. This is further corroborated by the negative EBITDA of -$14.59 million, which points to ongoing operational losses.
Probe a little deeper into the valuation metrics and a nuanced picture begins to crystallize. While the Trailing PE and Forward PE stand at 0, indicating no earnings to compare the share price against, a Price to Sales (P/S) ratio of 3.899 reflects a moderate market valuation of the company's sales.
Comments
